PLoS Pathogens (Dec 2014)

Murine anti-vaccinia virus D8 antibodies target different epitopes and differ in their ability to block D8 binding to CS-E.

  • Michael H Matho,
  • Natalia de Val,
  • Gregory M Miller,
  • Joshua Brown,
  • Andrew Schlossman,
  • Xiangzhi Meng,
  • Shane Crotty,
  • Bjoern Peters,
  • Yan Xiang,
  • Linda C Hsieh-Wilson,
  • Andrew B Ward,
  • Dirk M Zajonc

DOI
https://doi.org/10.1371/journal.ppat.1004495
Journal volume & issue
Vol. 10, no. 12
p. e1004495

Abstract

Read online

The IMV envelope protein D8 is an adhesion molecule and a major immunodominant antigen of vaccinia virus (VACV). Here we identified the optimal D8 ligand to be chondroitin sulfate E (CS-E). CS-E is characterized by a disaccharide moiety with two sulfated hydroxyl groups at positions 4' and 6' of GalNAc. To study the role of antibodies in preventing D8 adhesion to CS-E, we have used a panel of murine monoclonal antibodies, and tested their ability to compete with CS-E for D8 binding. Among four antibody specificity groups, MAbs of one group (group IV) fully abrogated CS-E binding, while MAbs of a second group (group III) displayed widely varying levels of CS-E blocking. Using EM, we identified the binding site for each antibody specificity group on D8. Recombinant D8 forms a hexameric arrangement, mediated by self-association of a small C-terminal domain of D8. We propose a model in which D8 oligomerization on the IMV would allow VACV to adhere to heterogeneous population of CS, including CS-C and potentially CS-A, while overall increasing binding efficiency to CS-E.